Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 5
Multidisciplinary Approaches to Managing AEs with Bispecifics
Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE profiles of talquetamab, teclistamab, and elranatamab, highlighting unique challenges and benefits.
Video content above is prompted by the following:
- What multidisciplinary approaches have you found most effective in managing the diverse range of AEs associated with bispecific therapies?
- Based on your experience, how do the AE profiles of talquetamab compare with those of other bispecific therapies like teclistamab or elranatamab?
- Are there any unique challenges or benefits you’ve observed?
Recent Videos
Related Content
